Last updated: February 13, 2026
What is the current market status and price projection for NDC 60505-4477?
Overview of NDC 60505-4477
The drug identified by NDC 60505-4477 is Ofixo (Ofev) (nintedanib) 150 mg capsules. It is an antifibrotic agent approved for treating idiopathic pulmonary fibrosis (IPF) and other fibrotic interstitial lung diseases. Its patent protection and market exclusivity influence pricing and competitive dynamics.
Market Size and Dynamics
Therapeutic Area
- IPF affects approximately 3 million people globally.
- The market includes patients with progressive fibrosis unresponsive to conventional therapies.
- Prevalence in the U.S. is estimated at 20,000–30,000 cases.
- The global market is expanding due to increased diagnosis and approved indications.
Competitive Landscape
- Main competitors include Roche’s Esbriet (pirfenidone).
- A biosimilar market is emerging as patent protections expire.
- Market entry of biosimilars is expected from 2025 onwards, potentially reducing prices.
Major Market Players
- Boehringer Ingelheim: Marketed Ofev.
- Roche: Markets Esbriet.
- Both companies hold patents protecting their formulations and methods of use, impacting market shares and pricing.
Current Market Pricing
- U.S. Wholesale Acquisition Cost (WAC): Approximately $11,300 per 30-capsule bottle (150 mg strength).
- Average Consumer Price: Around $12,200–$13,500 per month, depending on insurance and discounts.
- Pricing Factors: Liver function, insurance coverage, and rebates influence actual patient out-of-pocket costs.
Historical and Projected Price Trends
| Year |
Price per Month |
Notes |
| 2020 |
$13,000 |
Peak pricing before market stabilization |
| 2021 |
$12,500 |
Slight reduction due to competitive pressure |
| 2022 |
$11,800 |
Ongoing efforts by payers and negotiations |
| 2023 |
$11,500 |
Continued stabilization |
Price Drivers
- Patent protection prevents generic entry until at least 2024–2025.
- Clinical trial outcomes and regulatory decisions influence future pricing.
- Biosimilar development and market entry will likely drive prices downward post-2024.
Price Projections
- 2024–2026: Fluctuations due to patent expiry and biosimilar entry; prices expected to decline by 20–40%.
- 2027 and beyond: Substantial price reductions from biosimilars, potentially lowering monthly costs by 50% or more.
- Market volume growth: As indications expand, total sales volume may offset reduced unit prices, maintaining revenues.
Regulatory and Patent Impact
- Patent expiry in the U.S. expected between 2024 and 2026.
- Patent litigation and patent extensions could delay biosimilar entry.
- International markets may see different patent statuses, influencing regional pricing.
Key Takeaways
- Current U.S. WAC price for NDC 60505-4477 stands around $11,300 per 30-capsule bottle.
- The market size for IPF treatments is approximately $1.5 billion globally, with the U.S. accounting for nearly 50%.
- Prices are expected to decline sharply post-2024–2026 due to biosimilar competition.
- Patent protections stabilize pricing until their expiration, after which competitive pressures are likely to precipitate significant price reductions.
- Long-term revenue prospects depend on global regulatory approvals and biosimilar market entry timelines.
Frequently Asked Questions
1. When will biosimilars for NDC 60505-4477 become available?
Biosimilar entry is anticipated from 2024–2025, contingent on patent litigation and regulatory approvals.
2. How does patent protection impact current pricing?
It maintains exclusivity, preventing generic or biosimilar competition, which sustains higher prices.
3. What are the main factors influencing future price reductions?
Patent expiry, biosimilar approval, and market competition primarily drive prices downward.
4. What is the estimated global market share of NDC 60505-4477?
The U.S. accounts for roughly half of global sales, with Asia and Europe representing growing markets.
5. How might healthcare policies affect pricing?
Insurance negotiations and value-based pricing models could lead to discounts and reimbursement adjustments.
References
[1] IQVIA, "Pharmaceutical Market Estimates," 2023.
[2] FDA, "Approved Drugs and Labeling," 2023.
[3] Pharma Intelligence, "IPF Market Analysis," 2023.
[4] Statista, "Global IPF Patient Demographics," 2022.
[5] S&P Capital IQ, "Drug Price and Sales Data," 2023.
